Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $1.28 billion. The enterprise value is $795.77 million.
| Market Cap | 1.28B |
| Enterprise Value | 795.77M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SYRE has 50.78 million shares outstanding. The number of shares has increased by 868.38% in one year.
| Shares Outstanding | 50.78M |
| Shares Change (YoY) | +868.38% |
| Shares Change (QoQ) | +429.39% |
| Owned by Insiders (%) | 5.51% |
| Owned by Institutions (%) | 49.50% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,861.53 |
| Forward PS | n/a |
| PB Ratio | 8.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,156.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.38, with zero debt.
| Current Ratio | 11.38 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -113.80% |
| Return on Capital (ROIC) | -178.15% |
| Revenue Per Employee | $22,933 |
| Profits Per Employee | -$12.14M |
| Employee Count | 30 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SYRE has paid $42,000 in taxes.
| Income Tax | 42,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +130.23% in the last 52 weeks. The beta is 2.85, so SYRE's price volatility has been higher than the market average.
| Beta (5Y) | 2.85 |
| 52-Week Price Change | +130.23% |
| 50-Day Moving Average | 32.24 |
| 200-Day Moving Average | 24.82 |
| Relative Strength Index (RSI) | 39.06 |
| Average Volume (20 Days) | 1,099,830 |
Short Selling Information
The latest short interest is 4.84 million, so 9.54% of the outstanding shares have been sold short.
| Short Interest | 4.84M |
| Short Previous Month | 4.58M |
| Short % of Shares Out | 9.54% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.51 |
Income Statement
In the last 12 months, SYRE had revenue of $688,000 and -$364.23 million in losses. Loss per share was -$46.84.
| Revenue | 688,000 |
| Gross Profit | 688,000 |
| Operating Income | -271.27M |
| Pretax Income | -364.18M |
| Net Income | -364.23M |
| EBITDA | -363.77M |
| EBIT | -364.18M |
| Loss Per Share | -$46.84 |
Balance Sheet
The company has $484.96 million in cash and no debt, giving a net cash position of $484.96 million or $9.55 per share.
| Cash & Cash Equivalents | 484.96M |
| Total Debt | n/a |
| Net Cash | 484.96M |
| Net Cash Per Share | $9.55 |
| Equity (Book Value) | 152.27M |
| Book Value Per Share | 3.00 |
| Working Capital | 444.46M |
Cash Flow
In the last 12 months, operating cash flow was -$110.82 million and capital expenditures $475,000, giving a free cash flow of -$110.34 million.
| Operating Cash Flow | -110.82M |
| Capital Expenditures | 475,000 |
| Free Cash Flow | -110.34M |
| FCF Per Share | -$3.02 |
Margins
Gross margin is 100.00%, with operating and profit margins of -39,428.92% and -52,939.68%.
| Gross Margin | 100.00% |
| Operating Margin | -39,428.92% |
| Pretax Margin | -52,933.58% |
| Profit Margin | -52,939.68% |
| EBITDA Margin | -52,873.11% |
| EBIT Margin | -52,933.58% |
| FCF Margin | -16,038.23% |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -868.38% |
| Shareholder Yield | -868.38% |
| Earnings Yield | -28.44% |
| FCF Yield | -8.62% |
Analyst Forecast
The average price target for SYRE is $43.00, which is 70.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $43.00 |
| Price Target Difference | 70.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -17.43% |
| EPS Growth Forecast (5Y) | -39.43% |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
SYRE has an Altman Z-Score of 5.69 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.69 |
| Piotroski F-Score | 2 |